Journal Home > Volume 7 , Issue 1

The Neurorestoratology discipline is getting worldwide attention from the clinicians, basic scientists, students and policy makers alike. Accordingly, this year too, the discipline has made profound advances and great achievements for the benefit of the mankind. In this report, of the 2018 Neurorestoratology Yearbook, salient features of new developments are summarized. This Yearbook consists 3 key themes namely (i) the new findings on pathogenesis of neurological diseases or degeneration; (ii) the new mechanisms of neurorestorative aspects; and (iii) the achievements and progresses made in the clinical field of neurorestorative therapies. The new trend has emerged in clinical studies that are based on greater levels of evidence-based medical practices both in clinical therapies and clinical trials based on standard designs.


menu
Abstract
Full text
Outline
About this article

2018 Yearbook of Neurorestoratology

Show Author's information Hongyun Huang1,2( )Hari Shanker Sharma3Lin Chen4Hooshang Saberi5Gengsheng Mao1
Institute of Neurorestoratology, Third Medical Center of General Hospital of PLA, Beijing, China
Cell Therapy Center, Beijing Hongtianji Neuroscience Academy, Beijing, China
Int. Exp. CNS Injury & Repair, Anesthesiology & Intensive Care Medicine, Department of Surgical Sciences, University Hospital, Uppsala University, Sweden
Department of Neurorestoratology, Tsinghua University Yuquan Hospital, Beijing, China
Brain and Spinal Research Center, Department of Neurosurgery, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran

Abstract

The Neurorestoratology discipline is getting worldwide attention from the clinicians, basic scientists, students and policy makers alike. Accordingly, this year too, the discipline has made profound advances and great achievements for the benefit of the mankind. In this report, of the 2018 Neurorestoratology Yearbook, salient features of new developments are summarized. This Yearbook consists 3 key themes namely (i) the new findings on pathogenesis of neurological diseases or degeneration; (ii) the new mechanisms of neurorestorative aspects; and (iii) the achievements and progresses made in the clinical field of neurorestorative therapies. The new trend has emerged in clinical studies that are based on greater levels of evidence-based medical practices both in clinical therapies and clinical trials based on standard designs.

Keywords:

yearbook, neurorestoratology, pathogenesis, diseases and damage to the nervous system, neurorestorative mechanisms, neurorestorative therapies
Received: 05 January 2019 Revised: 17 January 2019 Accepted: 22 January 2019 Published: 22 March 2019 Issue date: March 2019
References(71)
[1]
H Hampel, MM Mesulam, AC Cuello, et al. Revisiting the cholinergic hypothesis in Alzheimer’s disease: Emerging evidence from translational and clinical research. J Prev Alzheimers Dis. 2019, 6(1): 2-15.
[2]
TE Cope, T Rittman, RJ Borchert, et al. Tau burden and the functional connectome in Alzheimer’s disease and progressive supranuclear palsy. Brain. 2018, 141(2): 550-567.
[3]
N Musi, JM Valentine, KR Sickora, et al. Tau protein aggregation is associated with cellular senescence in the brain. Aging Cell. 2018, 17(6): e12840.
[4]
Y Wei, MR Shin, F Sesti. Oxidation of KCNB1 channels in the human brain and in mouse model of Alzheimer’s disease. Cell Death Dis. 2018, 9(8): 820.
[5]
A Gatt, A Ekonomou, A Somani, et al. Importance of proactive treatment of depression in Lewy body dementias: The impact on hippocampal neurogenesis and cognition in a post-mortem study. Dement Geriatr Cogn Disord. 2017, 44(5–6): 283-293.
[6]
ZX Hu, WN Song, XD Lu, et al. Peripheral T lymphocyte immunity and l-dopamine in patients with Parkinson’s disease. J Biol Regul Homeost Agents. 2018, 32(3): 687-691.
[7]
AF Pardiñas, P Holmans, AJ Pocklington, et al. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nat Genet. 2018, 50(3): 381-389.
[8]
Y Shi, S Lin, KA Staats, et al. Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. Nat Med. 2018, 24(3): 313-325.
[9]
SF Sorrells, MF Paredes, A Cebrian-Silla, et al. Human hippocampal neurogenesis drops sharply in children to undetectable levels in adults. Nature. 2018, 555(7696): 377-381.
[10]
M Boldrini, CA Fulmore, AN Tartt, et al. Human hippocampal neurogenesis persists throughout aging. Cell Stem Cell. 2018, 22(4): 589-599.
[11]
CH Nijboer, E Kooijman, CT van Velthoven, et al. Intranasal stem cell treatment as a novel therapy for subarachnoid hemorrhage. Stem Cells Dev. 2018, 27(5): 313-325.
[12]
T Kunath, A Natalwala, C Chan, et al. Are PARKIN patients ideal candidates for dopaminergic cell replacement therapies? Eur J Neurosci. 2018, 49(4): 453-462.
[13]
JA da Silva, F Tecuapetla, V Paixão, et al. Dopamine neuron activity before action initiation gates and invigorates future movements. Nature. 2018, 554(7691): 244-248.
[14]
C Liu, L Kershberg, J Wang, et al. Dopamine secretion is mediated by sparse active zone-like release sites. Cell. 2018, 172(4): 706-718.
[15]
S Konermann, P Lotfy, NJ Brideau, et al. Transcriptome engineering with RNA-targeting Type VI-D CRISPR effectors. Cell. 2018, 173(3): 665-676.e14.
[16]
M Pignatelli, TJ Ryan, DS Roy, et al. Engram cell excitability state determines the efficacy of memory retrieval. Neuron. 2019, 101(2): 274-284.e5.
[17]
TJ Bussian, A Aziz, CF Meyer, et al. Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. Nature. 2018, 562(7728): 578-582.
[18]
TA Bedrosian, C Quayle, N Novaresi, et al. Early life experience drives structural variation of neural genomes in mice. Science. 2018, 359(6382): 1395-1399.
[19]
AD Levi, KD Anderson, DO Okonkwo, et al. Clinical outcomes from a multi-center study of human neural stem cell transplantation in chronic cervical spinal cord injury. J Neurotrauma. 2018.
[20]
LH Guadalajara, AM León, CJ Vaquero, et al. Objective demonstration of improvement of neurogenic bowel dysfunction in a case of spinal cord injury following stem cell therapy. J Surg Case Rep. 2018, 2018(11): rjy300.
[21]
J Vaquero, M Zurita, MA Rico, et al. Intrathecal administration of autologous mesenchymal stromal cells for spinal cord injury: Safety and efficacy of the 100/3 guideline. Cytotherapy. 2018, 20(6): 806-819.
[22]
J Vaquero, M Zurita, MA Rico, et al. Cell therapy with autologous mesenchymal stromal cells in post-traumatic syringomyelia. Cytotherapy. 2018, 20(6): 796-805.
[23]
J Vaquero, M Zurita, MA Rico, et al. Intrathecal administration of autologous bone marrow stromal cells improves neuropathic pain in patients with spinal cord injury. Neurosci Lett. 2018, 670: 14-18.
[24]
AJ Santamaría, FD Benavides, DL DiFede, et al. Clinical and neurophysiological changes after targeted intrathecal injections of bone marrow stem cells in a C3 tetraplegic subject. J Neurotrauma. 2018, 36(3).
[25]
GA Moviglia, MTM Brandolino, D Couto, et al. Local immunomodulation and muscle progenitor cells induce recovery in atrophied muscles in spinal cord injury patients. J Neurorestoratology. 2018, 6(1): 136-145.
[26]
S Al Kandari, L Prasad, M Al Kandari, et al. Cell transplantation and clinical reality: Kuwait experience in persons with spinal cord injury. Spinal Cord. 2018, 56(7): 674-679.
[27]
NT Liem, VD Chinh, NT Thinh, et al. Improved bowel function in patients with spina bifida after bone marrow- derived mononuclear cell transplantation: A report of 2 cases. Am J Case Rep. 2018, 19: 1010-1018.
[28]
PH Sung, HS Lin, WC Lin, et al. Intra-carotid arterial transfusion of autologous circulatory derived CD34+ cells for old ischemic stroke patients - a phase I clinical trial to evaluate safety and tolerability. Am J Transl Res. 2018, 10(9): 2975-2989.
[29]
SI Savitz, D Yavagal, G Rappard, et al. A phase 2 randomized, sham-controlled trial of internal carotid artery infusion of autologous bone marrow derived ALD-401 cells in patients with recent stable ischemic stroke (RECOVER-Stroke). Circulation. 2018, 139(2): 192-205.
[30]
DT Laskowitz, ER Bennett, RJ Durham, et al. Allogeneic umbilical cord blood infusion for adults with ischemic stroke: Clinical outcomes from a phase I safety study. Stem Cells Transl Med. 2018, 7(7): 521-529.
[31]
CG van Horne, JE Quintero, JT Slevin, et al. Peripheral nerve grafts implanted into the substantia nigra in patients with Parkinson’s diseaseduring deep brain stimulation surgery: 1-year follow-up study of safety, feasibility, and clinical outcome. J Neurosurg. 2018, 129(6): 1550-1561.
[32]
TL Nguyen, HP Nguyen, TK Nguyen. The effects of bone marrow mononuclear cell transplantation on the quality of life of children with cerebral palsy. Health Qual Life Outcomes. 2018, 16(1): 164.
[33]
C Elena, S Ekaterina, K Marina, et al. Monocyte-derived macrophages for treatment of cerebral palsy: A study of 57 cases. J Neurorestoratology. 2018, 6(1): 41-47.
[34]
L da Cruz, K Fynes, O Georgiadis, et al. Phase 1 clinical study of an embryonic stem cell-derived retinal pigment epithelium patch in age-related macular degeneration. Nat Biotechnol. 2018, 36(4): 328-337.
[35]
G Mao, Y Wang, X Guo, et al. Neurorestorative effect of olfactory ensheathing cells and Schwann cells by intranasal delivery for patients with ischemic stroke: Design of a multicenter randomized double-blinded placebo-controlled clinical study. J Neurorestoratology. 2018, 6(1): 74-80.
[36]
TG Phan, H Ma, R Lim, et al. Phase 1 trial of amnion cell therapy for ischemic stroke. Front Neurol. 2018, 9: 198.
[37]
L Deng, Q Peng, H Wang, et al. Intrathecal injection of allogenic bone marrow-derived mesenchymal stromal cells in treatment of patients with severe ischemic stroke: Study protocol for a randomized controlled observer-blinded trial. Transl Stroke Res. 2018: 1-8.
[38]
T Osanai, K Houkin, S Uchiyama, et al. Treatment evaluation of acute stroke for using in regenerative cell elements (TREASURE) trial: Rationale and design. Int J Stroke. 2018, 13(4): 444-448.
[39]
I Garitaonandia, R Gonzalez, G Sherman, et al. Novel approach to stem cell therapy in Parkinson’s disease. Stem Cells Dev. 2018, 27(14): 951-957.
[40]
JF Loring. Autologous induced pluripotent stem cell-derived neurons to treat Parkinson’s disease.Stem Cells Dev. 2018, 27(14): 958-959.
[41]
N Cichoń, M Bijak, P Czarny, et al. Increase in blood levels of growth factors involved in the neuroplasticity process by using an extremely low frequency electromagnetic field in post-stroke patients. Front Aging Neurosci. 2018, 10: 294.
[42]
CA Angeli, M Boakye, RA Morton, et al. Recovery of over- ground walking after chronic motor complete spinal cord injury. N Engl J Med. 2018, 379(13): 1244-1250.
[43]
ML Gill, PJ Grahn, JS Calvert, et al. Neuromodulation of lumbosacral spinal networks enables independent stepping after complete paraplegia. Nat Med. 2018, 24(11): 1677-1682.
[44]
AN Herrity, CS Williams, CA Angeli, et al. Lumbosacral spinal cord epidural stimulation improves voiding function after human spinal cord injury. Sci Rep. 2018, 8(1): 8688.
[45]
DGL Terson de Paleville, SJ Harkema, CA Angeli. Epidural stimulation with locomotor training improves body composition in individuals with cervical or upper thoracic motor complete spinal cord injury: A series of case studies. J Spinal Cord Med. 2018, 42(1): 1-7.
[46]
FB Wagner, JB Mignardot, CG Le Goff-Mignardot, et al. Targeted neurotechnology restores walking in humans with spinal cord injury. Nature. 2018, 563: 65-71.
[47]
SJ Harkema, S Wang, CA Angeli, et al. Normalization of blood pressure with spinal cord epidural stimulation after severe spinal cord injury. Front Hum Neurosci. 2018, 12: 83.
[48]
SC Aslan, BE Legg Ditterline, MC Park, et al. Epidural spinal cord stimulation of lumbosacral networks modulates arterial blood pressure in individuals with spinal cord injury- induced cardiovascular deficits. Front Physiol. 2018, 9: 565.
[49]
R Poiani, AL Zaninotto, AMC Carneiro, et al. Photobiomodulation using low-level laser therapy (LLLT) for patients with chronic traumatic brain injury: A randomized controlled trial study protocol. Trials. 2018, 19(1): 17.
[50]
JGRPD Santos, ALC Zaninotto, RA Zângaro, et al. Effects of transcranial LED therapy on the cognitive rehabilitation for diffuse axonal injury due to severe acute traumatic brain injury: Study protocol for a randomized controlled trial. Trials. 2018, 19(1): 249.
[51]
T da Silva, FC da Silva, AO Gomes, et al. Effect of photobiomodulation treatment in the sublingual, radial artery region, and along the spinal column in individuals with multiple sclerosis: Protocol for a randomized, controlled, double-blind, clinical trial. Medicine (Baltimore). 2018, 97(19):e0627.
[52]
S Falci, C Indeck, D Barnkow. Spinal cord injury below- level neuropathic pain relief with dorsal root entry zone microcoagulation performed caudal to level of complete spinal cord transection.J Neurosurg Spine. 2018, 28(6): 612-620.
[53]
H Huang, Z Al Zoubi. A brief introduction to the Special Issue on clinical treatment of spinal cord injury. J Neurorestoratology. 2018, 6: 134-135.
[54]
CC Ko, TH Tu, JC Wu, et al. Functional improvement in chronic human spinal cord injury: Four years after acidic fibroblast growth factor. Sci Rep. 2018, 8(1): 12691.
[55]
N Derakhshanrad, H Saberi, MS Yekaninejad, et al. Subcutaneous granulocyte colony-stimulating factor administration for subacute traumatic spinal cord injuries, report of neurological and functional outcomes: A double-blind randomized controlled clinical trial. J Neurosurg Spine. 2018: 1-12.
[56]
N Derakhshanrad, H Saberi, MS Yekaninejad, et al. Granulocyte-colony stimulating factor administration for neurological improvement in patients with postrehabilitation chronic incomplete traumatic spinal cord injuries: a double- blind randomized controlled clinical trial.J Neurosurg Spine. 2018, 29(1): 97-107.
[57]
CM McDonald, B Wong, KM Flanigan, et al. Placebo- controlled phase 2 trial of drisapersen for Duchenne Muscular Dystrophy. Ann Clin Transl Neurol. 2018, 5(8): 913-926.
[58]
F Panza, D Seripa, M Lozupone, et al. The potential of solanezumab and gantenerumab to prevent Alzheimer’s disease in people with inherited mutations that cause its early onset. Expert Opin Biol Ther. 2018, 18(1): 25-35.
[59]
KA Strauss, VJ Carson, KW Brigatti, et al. Preliminary safety and tolerability of a novel subcutaneous intrathecal catheter system for repeated outpatient dosing of nusinersen to children and adults with spinal muscular atrophy. J Pediatr Orthop. 2018, 38(10): e610-e617.
[60]
O Eckstein, CL McAtee, J Greenberg, et al. Rituximab therapy for patients with Langerhans cell histiocytosis-associated neurologic dysfunction. Pediatr Hematol Oncol. 2018: 1-7.
[61]
K Kucher, D Johns, D Maier, et al. First-in-man intrathecal application of neurite growth-promoting Anti-Nogo-A antibodies in acute spinal cord injury. Neurorehab Neural Re. 2018, 32(6–7): 578-589.
[62]
CH Hubscher, AN Herrity, CS Williams, et al. Improvements in bladder, bowel and sexual outcomes following task-specific locomotor training in human spinal cord injury. PLoS One. 2018, 13(1): e0190998.
[63]
BM Sandroff, RW Motl, M Bamman, et al. Rationale and design of a single-blind, randomised controlled trial of exercise training for managing learning and memory impairment in persons with multiple sclerosis. BMJ Open. 2018, 8(12): e023231.
[64]
C Trento, ME Bernardo, A Nagler, S Kuçi, et al. Manufacturing mesenchymal stromal cells for the treatment of graft-versus- host disease: A survey among centers affiliated with the European society for blood and marrow transplantation. Biol Blood Marrow Tr. 2018, 24(11): 2365-2370.
[65]
Q Ao, J Xiao, Y Yu, et al. Standards for the culture and quality control of umbilical cord mesenchymal stromal cells for neurorestorative clinical application (2017). J Neurorestoratology. 2018, 6: 11-15.
[66]
S Feng, J Xiao, F Han, et al. Neurorestorative clinical application standards for the culture and quality control of neural progenitor/precursor cells (version 2017). J Neurorestoratology. 2018, 6: 115-119.
[67]
EM Horwitz, K Le Blanc, M Dominici, et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy. 2005, 7(5): 393-395.
[68]
M Dominici, K Le Blanc, I Mueller, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006, 8(4): 315-317.
[69]
J Galipeau, M Krampera, J Barrett, et al. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy. 2016, 18(2): 151-159.
[70]
H Huang, W Young, L Chen, et al. Clinical cell therapy guidelines for neurorestoration (IANR/CANR 2017). Cell Transplant. 2018, 27(2): 310-324.
[71]
M Bikson, B Paneri, A Mourdoukoutas, et al. Limited output transcranial electrical stimulation (LOTES-2017): Engineering principles, regulatory statutes, and industry standards for wellness, over-the-counter, or prescription devices with low risk. Brain Stimul. 2018, 11(1): 134-157.
Publication history
Copyright
Rights and permissions

Publication history

Received: 05 January 2019
Revised: 17 January 2019
Accepted: 22 January 2019
Published: 22 March 2019
Issue date: March 2019

Copyright

© The authors 2019

Rights and permissions

This article is published with open access at http://jnr.tsinghuajournals.com

Return